INmune Bio partners with CGT Catapult to scale CORDStrom manufacturing for commercial readiness

Inmune Bio, Inc.

Partnership with Cell and Gene Therapy Catapult aims to establish large-scale commercial manufacturing for cell therapy platforms.
Initial focus on scaling CORDStrom for RDEB; Phase 2 trial showed reduced pain/itch and improved skin integrity.
INmune estimates 4,000 children with intermediate-to-severe RDEB in US/UK/EU could benefit from CORDStrom.
Following CORDStrom, INmune plans to transition INKmune production to same facility for solid tumor trials.
Manufacturing will leverage CGT Catapult's Stevenage Innovation Centre and existing Royal Free Hospital base.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.